Adherex Technologies (FENC) Projected to Post Earnings on Thursday

Key Points

• Q3 2026 results are expected before market open November 12. Analysts forecast earnings of $0.096 per share and revenue of $18.87 million; the company’s previous quarter beat consensus on both earnings and revenue.
• Analysts have a “Moderate Buy” consensus and an average price target of $17. The six analyst ratings include four Buys, one Hold, and one Sell.
• Two insiders sold shares in late August, including CFO Robert Andrade, whose sale reduced his stake by 25.63%. The CFO’s sale was made under a pre-arranged Rule 10b5-1 plan.

Adherex Technologies (NASDAQ:FENC - Get Free Report) is expected to post its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of $0.0960 per share and revenue of $18.87 million for the quarter. Interested persons can find conference call details on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 12:30 PM ET.

Adherex Technologies (NASDAQ:FENC - Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03. The firm had revenue of $17.87 million during the quarter, compared to analyst estimates of $16.21 million. Adherex Technologies had a negative net margin of 6.09% and a negative return on equity of 5.71%. On average, analysts expect Adherex Technologies to post $0.28 EPS for the current fiscal year and $0.97 EPS for the next fiscal year.

Adherex Technologies Stock Performance

Shares of Adherex Technologies stock opened at $10.30 on Thursday. The firm has a 50-day simple moving average of $10.88 and a two-hundred day simple moving average of $9.26. The company has a market cap of $362.03 million, a P/E ratio of -79.25 and a beta of 1.29. Adherex Technologies has a fifty-two week low of $5.65 and a fifty-two week high of $13.25.

Insiders Place Their Bets

In other news, CFO Robert Andrade sold 75,000 shares of Adherex Technologies stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $11.78, for a total value of $883,500.00. Following the sale, the chief financial officer owned 217,675 shares in the company, valued at $2,564,211.50. This trade represents a 25.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pierre Sargis Sayad sold 12,000 shares of Adherex Technologies stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $12.18, for a total transaction of $146,160.00. Following the completion of the sale, the insider owned 9,519 shares in the company, valued at approximately $115,941.42. This trade represents a 55.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 10.73% of the company's stock.

Wall Street Analysts Forecast Growth

FENC has been the topic of a number of analyst reports. Wedbush raised their target price on Adherex Technologies from $13.00 to $16.00 and gave the company an "outperform" rating in a research report on Wednesday, August 12th. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price target on shares of Adherex Technologies in a report on Wednesday, September 9th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Adherex Technologies in a report on Thursday, October 15th. Finally, B. Riley Financial reiterated a "buy" rating and set a $18.00 price target (up from $16.00) on shares of Adherex Technologies in a research report on Wednesday, August 12th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $17.00.

Adherex Technologies Company Profile

Fennec Pharmaceuticals, Inc, formerly known as Adherex Technologies, is a biopharmaceutical company focused on developing and commercializing therapies for pediatric cancer. The company's lead product is PEDMARK (sodium thiosulfate), a platinum-based chemotherapy protective agent intended to reduce the risk of cisplatin-induced ototoxicity, or hearing loss, in children with localized, non-metastatic solid tumors.

PEDMARK received approval from the U.S. Food and Drug Administration in 2022.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.